MedTrace Logo

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

NCT06840535 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-01-06

No results posted yet for this study

Summary

The aim of this study is to assess the safety and dosimetry of \[68Ga\]Ga-OncoACP3 in patients with prostate cancer.

Conditions

  • Prostate Cancer
  • Prostate Cancer Metastatic Disease
  • PSA Level Greater Than 0.2

Interventions

DRUG

[68Ga]Ga-OncoACP3

Single intravenous bolus injection.

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-08
Primary Completion
2025-10-03
Completion
2025-10-03

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06840535 on ClinicalTrials.gov